NASDAQ:AMLX - Amylyx Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.33
  • Forecasted Upside: 363.60 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.70
▼ -0.32 (-3.55%)

This chart shows the closing price for AMLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amylyx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMLX

Analyst Price Target is $40.33
▲ +363.60% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Amylyx Pharmaceuticals in the last 3 months. The average price target is $40.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 363.60% upside from the last price of $8.70.

This chart shows the closing price for AMLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Amylyx Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2022Evercore ISIInitiated CoverageOutperformHigh
2/1/2022SVB LeerinkReiterated RatingOutperform$50.00High
2/1/2022The Goldman Sachs GroupInitiated CoverageBuy$36.00High
2/1/2022HC WainwrightReiterated RatingBuy$35.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
4/22/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.70
Low: $8.28
High: $9.17

50 Day Range

MA: $13.05
Low: $6.85
High: $25.00

52 Week Range

Now: $8.70
Low: $6.51
High: $33.41

Volume

295,080 shs

Average Volume

258,477 shs

Market Capitalization

$509.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Amylyx Pharmaceuticals?

The following sell-side analysts have issued reports on Amylyx Pharmaceuticals in the last twelve months: Evercore ISI, HC Wainwright, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AMLX.

What is the current price target for Amylyx Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Amylyx Pharmaceuticals in the last year. Their average twelve-month price target is $40.33, suggesting a possible upside of 363.6%.
View the latest price targets for AMLX.

What is the current consensus analyst rating for Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMLX will outperform the market and that investors should add to their positions of Amylyx Pharmaceuticals.
View the latest ratings for AMLX.

How do I contact Amylyx Pharmaceuticals' investor relations team?

The company's listed phone number is 617-683-0917 and its investor relations email address is [email protected] The official website for Amylyx Pharmaceuticals is amylyx.com. Learn More about contacing Amylyx Pharmaceuticals investor relations.